Siltuximab Shows Promising Efficacy Against CRS and ICANS
Researchers sought to determine whether siltuximab would be safe and effective for treating CRS and ICANS associated with CAR-T therapy.
Diagnosis & Disease Information
CAR-T Survival Outcomes Unrelated to Household Poverty and Neighborhood Opportunity in ALL
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Ide-Cel Bests Standard Care in Relapsed/Refractory Multiple Myeloma
Ide-cel improves outcomes in patients with triple-class-exposed multiple myeloma, when compared with standard care, a phase 3 trial suggests.
CAR-T Therapy Shows Promise in Primary and Secondary CNS Lymphomas
Researchers sought to determine whether CR rates were improved using CAR-T therapy in patients with central nervous system lymphoma.
Lisocabtagene Maraleucel Improves Health-Related Quality of Life in Large B-Cell Lymphoma
Researchers sought to determine whether lisocabtagene maraleucel would improve health-related quality of life in patients with relapsed/refractory LBCL.
Race, Ethnicity, Obesity Have No Significant Impact on CAR-T Therapy Efficacy in B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR-T therapy in patients with B-ALL.
Unmet Need Seen in Patients With B-Cell Lymphoma Who Fail CAR-T Therapy
Researchers sought to determine the unmet need in patients with aggressive B-cell lymphomas whose disease relapses after CAR-T therapy.
Researchers Identify 28 Early Signs of CAR T-Cell Toxicity
Researchers say they have identified 28 signs and symptoms that can facilitate early recognition of toxicity associated with CAR T-cell therapy.
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Addition of Anti-CD19 CAR-T to Ibrutinib Yields Deep, Durable Remissions in Chronic Lymphocytic Leukemia
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...